Sandoz opens new 150 million-euro biopharma production facility in Austria

Sandoz, the generics and biosimilars business of Swiss pharma giant Novartis (NOVN: VX), last week officially opened its new cutting-edge biomanufacturing facility called BioInject, at Schaftenau in the Tyrolean Alps in Austria.

This is the result of over 150 million euros (~$170 million) worth of investment with the creation of 100 highly skilled jobs.

BioInject is a state-of-the-art facility that will be used to manufacture pre-filled syringes and devices for both Sandoz’s biosimilars and Novartis Pharma’s novel biologics. This new facility now means that 18,000 syringes can be filled per hour and 100 packaged per minute. It will play an important role in driving the next wave of biosimilars and novel biologics growth at Sandoz and Novartis Pharmaceuticals - growth that will ultimately help address unmet medical needs and broaden patient access to key biologics products.